Phospho-CDH5 (Tyr731) Antibody

What is CDH5 and what is the significance of Tyr731 phosphorylation?

Cadherin 5 (CDH5), also known as VE-cadherin, is a calcium-dependent cell adhesion protein predominantly expressed in endothelial cells. CDH5 plays a crucial role in endothelial cell biology by controlling the cohesion and organization of intercellular junctions. It associates with alpha-catenin to form links to the cytoskeleton and works in concert with KRIT1 to establish and maintain correct endothelial cell polarity and vascular lumen formation .

Phosphorylation at Tyrosine 731 (Tyr731) represents a critical regulatory modification that influences adherens junction stability. When CDH5 becomes phosphorylated at this residue, it typically correlates with increased vascular permeability and barrier dysfunction. Research has demonstrated that this phosphorylation event is often increased during inflammatory conditions and contributes to the disruption of endothelial barrier integrity . The site-specific phosphorylation serves as a molecular switch that can regulate the association of CDH5 with its binding partners and ultimately affects the cohesiveness of adherens junctions.

How does CDH5 phosphorylation influence vascular permeability in different physiological systems?

Phosphorylation of CDH5 at Tyr731 directly impacts vascular permeability across multiple organ systems. In pulmonary tissues, enhanced CDH5 phosphorylation correlates with increased endothelial barrier dysfunction during acute lung injury (ALI). Studies have shown that LPS exposure downregulates protective factors like RAB26 while increasing CDH5 phosphorylation, leading to adherens junction destruction and increased vascular leakage .

In ocular tissues, particularly in the Schlemm's canal (SC) inner wall, CDH5 phosphorylation regulates aqueous humor outflow and intraocular pressure (IOP). Research has demonstrated that the amount of flow tracer at cell junctions (marked by CDH5) increases with rising IOP, indicating enhanced junctional permeability. This increased permeability correlates with elevated pY658-CDH5 and activated SRC family kinases (SFKs) at the SC endothelial cell adherens junctions .

The phosphorylation status of CDH5 thus represents a conserved regulatory mechanism across different vascular beds, allowing context-specific modulation of barrier function in response to physiological demands or pathological insults.

What are the validated applications for Phospho-CDH5 (Tyr731) antibody in vascular research?

The Phospho-CDH5 (Tyr731) antibody has been validated for multiple experimental applications that are essential for vascular research. Based on current specifications, these include:

The antibody shows confirmed reactivity with human and mouse samples, making it versatile for translational research . When designing experiments, researchers should consider that optimal dilutions may need to be determined empirically depending on specific experimental conditions and sample types.

For studying dynamic changes in CDH5 phosphorylation, researchers have successfully employed this antibody in time-course experiments following various stimuli, including inflammatory mediators and vascular permeability-inducing factors.

How should researchers design proper controls when working with Phospho-CDH5 (Tyr731) antibody?

Designing appropriate controls is essential for generating reliable data with phospho-specific antibodies. For Phospho-CDH5 (Tyr731) research, incorporate these controls:

• Phosphatase Treatment Control: Treat duplicate samples with lambda phosphatase before immunoblotting to confirm phospho-specificity. The signal should disappear in phosphatase-treated samples while total CDH5 remains detectable.

• Stimulation Controls: Include samples from cells treated with known inducers of CDH5 phosphorylation (e.g., LPS, VEGF, or thrombin) alongside untreated samples to demonstrate dynamic regulation.

• Tyrosine Kinase Inhibitor Controls: Pre-treatment of samples with SRC family kinase inhibitors should reduce Tyr731 phosphorylation, providing evidence of pathway specificity .

• Genetic Controls: When possible, use CDH5 mutant constructs where Tyr731 is replaced with phenylalanine (Y731F) to demonstrate antibody specificity.

• Total Protein Control: Always probe for total CDH5 protein in parallel to normalize phospho-signal to total protein levels.

The immunogen used for antibody generation (synthesized peptide derived from human VE-Cadherin around the phosphorylation site of Y731) provides a reference point for specificity validation . For comprehensive validation, consider analyzing samples from models with known alterations in CDH5 phosphorylation, such as RAB26-deficient systems which exhibit increased CDH5 phosphorylation .

How can Phospho-CDH5 (Tyr731) antibody be used to investigate signaling pathways regulating vascular barrier function?

The Phospho-CDH5 (Tyr731) antibody offers a powerful tool for dissecting the complex signaling networks that regulate vascular barrier integrity. Researchers can implement several sophisticated approaches:

First, combine Phospho-CDH5 (Tyr731) antibody with antibodies against upstream kinases, particularly SRC family kinases (SFKs), to map activation cascades. Co-immunoprecipitation studies can reveal direct interactions between CDH5 and regulatory proteins at adherens junctions. Research has demonstrated that FYN, but not SRC, is expressed in Schlemm's canal endothelial cells (SECs) and is responsible for CDH5 phosphorylation at tyrosine residues, including Y658 and Y685 .

Time-course experiments following stimulation with permeability-inducing factors can establish the temporal dynamics of phosphorylation events. This approach reveals whether CDH5 phosphorylation is an early or late event in barrier disruption cascades. Combining immunofluorescence with live-cell imaging techniques allows visualization of phosphorylated CDH5 trafficking and adherens junction remodeling in real-time.

For investigating pathway interactions, researchers have demonstrated that RAB26 levels are negatively correlated with CDH5 phosphorylation. RAB26 promotes autophagy-dependent degradation of phosphorylated SRC, which subsequently reduces CDH5 phosphorylation and maintains adherens junction integrity . This mechanism represents an important regulatory pathway that could be targeted therapeutically to prevent vascular leakage in conditions like acute lung injury.

What is the relationship between CDH5 Tyr731 phosphorylation and other tyrosine phosphorylation sites on VE-cadherin?

VE-cadherin (CDH5) contains multiple tyrosine residues that can be phosphorylated, creating a complex regulatory code that modulates adherens junction stability. Current research reveals important relationships between these phosphorylation sites:

Tyr731 phosphorylation often occurs in conjunction with phosphorylation at other sites, particularly Y658 and Y685. In studies of Schlemm's canal endothelial cells, increased junctional permeability correlated with both pY658-CDH5 and activated SFK at the adherens junctions . This suggests coordinated regulation of multiple phosphorylation sites during barrier modulation.

The kinase specificity for different tyrosine residues provides another layer of regulation. While the SRC family kinase FYN has been implicated in phosphorylating both Y658 and Y685 residues in SECs , the specific kinases responsible for Tyr731 phosphorylation may vary by cell type and context.

Different phosphorylation sites may have distinct functional consequences:

• Y731 phosphorylation appears particularly important for adherens junction integrity

• Y658 phosphorylation affects binding to p120-catenin

• Y685 may influence interactions with other junction components

When designing experiments to study CDH5 phosphorylation, researchers should consider analyzing multiple phosphorylation sites simultaneously to understand their cooperative effects on junction stability and barrier function.

What are common technical challenges when detecting Phospho-CDH5 (Tyr731) and how can they be resolved?

Researchers frequently encounter several technical challenges when working with phospho-specific antibodies, including the Phospho-CDH5 (Tyr731) antibody:

Challenge 1: Rapid dephosphorylation during sample preparation

• Solution: Use phosphatase inhibitor cocktails (containing sodium orthovanadate, sodium fluoride, and β-glycerophosphate) in all buffers during sample collection and processing.

• Maintain samples at 4°C throughout processing and avoid repeated freeze-thaw cycles as indicated in storage recommendations .

Challenge 2: Low signal intensity

• Solution: Optimize antibody concentration through titration experiments. While recommendations suggest 1:500-1:2000 for Western blot, empirical optimization is essential .

• Consider signal amplification systems that are compatible with phospho-epitopes.

• Ensure sample preparation methods effectively solubilize membrane-associated proteins by using appropriate detergents.

Challenge 3: Background or non-specific signals

• Solution: Increase blocking stringency using 5% BSA rather than milk (which contains phospho-proteins).

• Include additional washing steps and consider adding 0.1% Tween-20 to wash buffers.

• Use the phosphopeptide competition assay to confirm signal specificity.

Challenge 4: Inconsistent results between experiments

• Solution: Standardize stimulation protocols that induce CDH5 phosphorylation.

• Use positive control samples from cells treated with known inducers of CDH5 phosphorylation.

• Ensure the antibody is stored appropriately (aliquoted at -20°C to avoid freeze-thaw cycles) .

For specialized applications like immunofluorescence, optimize fixation methods to preserve phospho-epitopes while maintaining tissue architecture. Paraformaldehyde fixation followed by careful permeabilization typically yields good results for phospho-CDH5 detection.

How can researchers quantitatively analyze changes in CDH5 Tyr731 phosphorylation in different experimental models?

Quantitative analysis of CDH5 Tyr731 phosphorylation requires rigorous methodological approaches to ensure reliable and reproducible results:

For Western Blot Analysis:

• Always normalize phospho-CDH5 (Tyr731) signal to total CDH5 protein levels to account for variations in protein expression or loading.

• Use densitometry software with linear range validation to ensure quantification occurs within the dynamic range of detection.

• Include gradient-loaded standards to create calibration curves for more precise quantification.

For Immunofluorescence Quantification:

• Employ co-staining with total CDH5 antibodies to calculate the ratio of phosphorylated to total protein at cell junctions.

• Use confocal microscopy with consistent acquisition parameters across samples.

• Apply automated image analysis algorithms to quantify signal intensity at defined regions of interest (cell-cell junctions).

For Flow Cytometry Applications:

• Develop protocols that preserve phospho-epitopes during cell preparation.

• Analyze the ratio of phospho-CDH5 to total CDH5 on a per-cell basis.

When comparing different experimental models, researchers should consider tissue-specific differences in CDH5 expression and regulation. For instance, the role of FYN in regulating CDH5 phosphorylation in Schlemm's canal endothelial cells may differ from regulatory mechanisms in pulmonary endothelial cells where RAB26 has been implicated in modulating CDH5 phosphorylation .

How should researchers interpret changes in CDH5 Tyr731 phosphorylation in the context of disease models?

Interpreting changes in CDH5 Tyr731 phosphorylation requires careful consideration of the biological context and experimental system. Here are key interpretive frameworks:

In acute lung injury (ALI) models, increased CDH5 phosphorylation generally correlates with barrier dysfunction and vascular leakage. Research has shown that mice lacking RAB26 exhibit increased CDH5 phosphorylation following LPS treatment, leading to adherens junction destruction and aggravated lung vascular permeability . Therefore, elevated Tyr731 phosphorylation in this context strongly suggests compromised barrier integrity.

For ocular research, particularly studies of intraocular pressure (IOP) regulation, CDH5 phosphorylation at the Schlemm's canal endothelial cell junctions correlates with increased junctional permeability. The amount of flow tracer at cell junctions increases with rising IOP, indicating enhanced permeability that facilitates aqueous humor drainage . In this specialized context, phosphorylation may represent an adaptive rather than pathological response.

Several interpretive principles should guide analysis:

• Always examine phosphorylation changes relative to total CDH5 levels to distinguish regulation of phosphorylation from changes in protein abundance.

• Consider the kinetics of phosphorylation - transient versus sustained changes may have different functional implications.

• Integrate data on CDH5 phosphorylation with functional measurements of barrier integrity (TEER, dextran flux, etc.) to establish causality.

• Acknowledge that phosphorylation at multiple sites may have synergistic or antagonistic effects on junction stability.

What are the known molecular interactions affected by CDH5 Tyr731 phosphorylation?

CDH5 Tyr731 phosphorylation influences multiple molecular interactions that collectively regulate adherens junction stability and vascular permeability:

Catenin Interactions:
Phosphorylation of CDH5 at Tyr731 can modulate its association with cytoplasmic catenin partners that link adherens junctions to the cytoskeleton. Under normal conditions, CDH5 associates with alpha-catenin, forming a link to the cytoskeleton that stabilizes cell-cell junctions . Phosphorylation can disrupt these interactions, weakening junctional integrity.

Internalization Pathways:
Phosphorylation at Tyr731 promotes CDH5 internalization, removing it from the cell surface and destabilizing adherens junctions. Research has shown that depletion of RAB26 enhances CDH5 phosphorylation and aggravates CDH5 internalization, thereby weakening adherens junction integrity and endothelial barrier function in human pulmonary microvascular endothelial cells .

Signaling Cascade Interactions:
Phosphorylated CDH5 participates in signaling cascades involving SRC family kinases (SFKs). In Schlemm's canal endothelial cells, FYN (an SFK family member) regulates site-specific phosphorylation of CDH5 at adherens junctions. The absence of FYN results in the loss of Y658 and Y685 CDH5 phosphorylation, suggesting interconnected regulation of multiple phosphorylation sites .

Autophagy Pathway Connections:
An interesting connection exists between CDH5 phosphorylation and autophagy pathways. RAB26 promotes autophagy-dependent degradation of phosphorylated SRC, thereby indirectly reducing CDH5 phosphorylation. This mechanism maintains adherens junction stabilization and protects barrier integrity during inflammatory challenges .

Understanding these molecular interactions provides potential intervention points for therapeutic strategies aimed at modulating vascular permeability in pathological conditions.